{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:42:42Z","timestamp":1784619762754,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["09150161910230"],"award-info":[{"award-number":["09150161910230"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sophia Children\u2019s Hospital Foundation","award":["S17-32"],"award-info":[{"award-number":["S17-32"]}]},{"DOI":"10.13039\/100016062","name":"Metakids","doi-asserted-by":"crossref","award":["2016-063"],"award-info":[{"award-number":["2016-063"]}],"id":[{"id":"10.13039\/100016062","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Economic Affairs under TKI-Allowance under the TKI-program Life Sciences & Health","award":["LSHM16008"],"award-info":[{"award-number":["LSHM16008"]}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.F16-03"],"award-info":[{"award-number":["W.F16-03"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Enzyme replacement therapy (ERT) with recombinant human alpha-glucosidase (rhGAA, alglucosidase alfa) has improved survival, motor outcomes, daily life activity and quality of life in Pompe patients. However, ERT in Pompe disease often induces formation of antibodies, which may reduce the efficacy of treatment and can lead to adverse events. In this study antibody formation and their effect on clinical outcome in patients with childhood onset Pompe disease treated with enzyme replacement therapy (ERT) with recombinant human alpha-glucosidase (rhGAA) are analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Enzyme-linked immunosorbent assay (ELISA) was used to determine anti-rhGAA antibody titers at predefined time points. The effect of antibodies on rhGAA activity (neutralizing effects) was measured in vitro. Clinical effects were evaluated by assessing muscle strength (MRC score) and function (QMFT-score), pulmonary function and infusion associated reactions (IARs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-two patients were included (age at start ERT 1.1\u201316.4\u00a0years, median treatment duration 12.4\u00a0years). Peak antibody titers were low (&lt;\u20091:1250) in 9%, intermediate (1:1250\u20131:31,250) in 68% and high (\u2265\u20091:31250) in 23% of patients; three patients (14%) had more than one titer of\u2009\u2265\u20091:31,250. Four patients (18%) experienced IARs; two patients from the high titer group had 86% of all IARs. Inhibition of intracellular GAA activity (58%) in vitro was found in one sample. The clinical course did not appear to be influenced by antibody titers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Ninety-one percent of childhood onset Pompe patients developed anti-rhGAA antibodies (above background level), a minority of whom had high antibody titers at repeated time points, which do not seem to interfere with clinical outcome. High antibody titers may be associated with the occurrence of IARs. Although the majority of patients does not develop high titers; antibody titers should be determined in case of clinical deterioration.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02175-2","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T19:02:22Z","timestamp":1643828542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Harmke A.","family":"van Kooten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke A. M.","family":"Ditters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Hoogeveen-Westerveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin H.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M. P.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. W. M. Pim","family":"Pijnappel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9161-3301","authenticated-orcid":false,"given":"Nadine A. M. E.","family":"van der Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"issue":"9646","key":"2175_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ. Pompe\u2019s disease. Lancet. 2008;372(9646):1342\u201353.","journal-title":"Lancet"},{"issue":"2","key":"2175_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1542\/peds.112.2.332","volume":"112","author":"HM van den Hout","year":"2003","unstructured":"van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332\u201340.","journal-title":"Pediatrics"},{"issue":"1","key":"2175_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13023-016-0442-y","volume":"11","author":"CI van Capelle","year":"2016","unstructured":"van Capelle CI, van der Meijden JC, van den Hout JM, Jaeken J, Baethmann M, Voit T, et al. Childhood Pompe disease: clinical spectrum and genotype in 31 patients. Orphanet J Rare Dis. 2016;11(1):65.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2175_CR4","first-page":"82","volume":"106","author":"NA van der Beek","year":"2006","unstructured":"van der Beek NA, Hagemans ML, van der Ploeg AT, Reuser AJ, van Doorn PA. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. Acta Neurol Belg. 2006;106(2):82\u20136.","journal-title":"Acta Neurol Belg"},{"issue":"23","key":"2175_CR5","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","volume":"89","author":"E Kuperus","year":"2017","unstructured":"Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der Meijden JC, et al. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study. Neurology. 2017;89(23):2365\u201373.","journal-title":"Neurology"},{"issue":"5","key":"2175_CR6","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","volume":"113","author":"JM Van den Hout","year":"2004","unstructured":"Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. 2004;113(5):e448\u201357.","journal-title":"Pediatrics"},{"key":"2175_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1750-1172-8-49","volume":"8","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, Kruijshaar ME, Plug I, D\u2019Agostino RB, Hagemans ML, van Doorn PA, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis. 2013;8:49.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2175_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10545-015-9889-6","volume":"39","author":"D G\u00fcng\u00f6r","year":"2016","unstructured":"G\u00fcng\u00f6r D, Kruijshaar ME, Plug I, Rizopoulos D, Kanters TA, Wens SC, et al. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. J Inherit Metab Dis. 2016;39(2):253\u201360.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2175_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99\u2013109.","journal-title":"Neurology"},{"issue":"4","key":"2175_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264(4):621\u201330.","journal-title":"J Neurol"},{"issue":"4","key":"2175_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10545-016-9917-1","volume":"39","author":"A Broomfield","year":"2016","unstructured":"Broomfield A, Jones SA, Hughes SM, Bigger BW. The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders. J Inherit Metab Dis. 2016;39(4):499\u2013512.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2175_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","volume":"38","author":"CM van Gelder","year":"2015","unstructured":"van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJ. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis. 2015;38(2):305\u201314.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2175_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26\u201333.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2175_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/gim.2016.70","volume":"19","author":"JM de Vries","year":"2017","unstructured":"de Vries JM, Kuperus E, Hoogeveen-Westerveld M, Kroos MA, Wens SC, Stok M, et al. Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy. Genet Med. 2017;19(1):90\u20137.","journal-title":"Genet Med"},{"issue":"4","key":"2175_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","volume":"101","author":"JM de Vries","year":"2010","unstructured":"de Vries JM, van der Beek NA, Kroos MA, Ozkan L, van Doorn PA, Richards SM, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab. 2010;101(4):338\u201345.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2175_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","volume":"106","author":"TT Patel","year":"2012","unstructured":"Patel TT, Banugaria SG, Case LE, Wenninger S, Schoser B, Kishnani PS. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab. 2012;106(3):301\u20139.","journal-title":"Mol Genet Metab"},{"key":"2175_CR17","doi-asserted-by":"publisher","first-page":"36182","DOI":"10.1038\/srep36182","volume":"6","author":"E Masat","year":"2016","unstructured":"Masat E, Lafor\u00eat P, De Antonio M, Corre G, Perniconi B, Taouagh N, et al. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients. Sci Rep. 2016;6:36182.","journal-title":"Sci Rep"},{"key":"2175_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ebiom.2019.03.048","volume":"43","author":"AJ Bergsma","year":"2019","unstructured":"Bergsma AJ, In \u2018t Groen SLM, van den Dorpel JJA, van den Hout H, van der Beek N, Schoser B, et al. A genetic modifier of symptom onset in Pompe disease. EBioMedicine. 2019;43:553\u201361.","journal-title":"EBioMedicine"},{"issue":"4","key":"2175_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/ana.20019","volume":"55","author":"LP Winkel","year":"2004","unstructured":"Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, et al. Enzyme replacement therapy in late-onset Pompe\u2019s disease: a three-year follow-up. Ann Neurol. 2004;55(4):495\u2013502.","journal-title":"Ann Neurol"},{"issue":"6","key":"2175_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.nmd.2008.04.009","volume":"18","author":"CI van Capelle","year":"2008","unstructured":"van Capelle CI, Winkel LP, Hagemans ML, Shapira SK, Arts WF, van Doorn PA, et al. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord. 2008;18(6):447\u201352.","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"2175_CR21","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/humu.23854","volume":"40","author":"MY Ni\u00f1o","year":"2019","unstructured":"Ni\u00f1o MY, In \u2018t Groen SLM, Bergsma AJ, van der Beek N, Kroos M, Hoogeveen-Westerveld M, et al. Extension of the Pompe mutation database by linking disease-associated variants to clinical severity. Hum Mutat. 2019;40(11):1954\u201367.","journal-title":"Hum Mutat"},{"issue":"6","key":"2175_CR22","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/jimd.12268","volume":"43","author":"E Poelman","year":"2020","unstructured":"Poelman E, van den Dorpel JJA, Hoogeveen-Westerveld M, van den Hout JMP, van der Giessen LJ, van der Beek N, et al. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients. J Inherit Metab Dis. 2020;43(6):1243\u201353.","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"2175_CR23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2011","unstructured":"Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, Ladda RL, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13(8):729\u201336.","journal-title":"Genet Med"},{"key":"2175_CR24","doi-asserted-by":"publisher","first-page":"100475","DOI":"10.1016\/j.ymgmr.2019.100475","volume":"20","author":"AK Desai","year":"2019","unstructured":"Desai AK, Kazi ZB, Bali DS, Kishnani PS. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy. Mol Genet Metab Rep. 2019;20:100475.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"2175_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13023-019-1039-z","volume":"14","author":"E Poelman","year":"2019","unstructured":"Poelman E, Hoogeveen-Westerveld M, van den Hout JMP, Bredius RGM, Lankester AC, Driessen GJA, et al. Effects of immunomodulation in classic infantile Pompe patients with high antibody titers. Orphanet J Rare Dis. 2019;14(1):71.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2175_CR26","doi-asserted-by":"publisher","first-page":"e98336","DOI":"10.1371\/journal.pone.0098336","volume":"9","author":"S Nayak","year":"2014","unstructured":"Nayak S, Doerfler PA, Porvasnik SL, Cloutier DD, Khanna R, Valenzano KJ, et al. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. PLoS ONE. 2014;9(6):e98336.","journal-title":"PLoS ONE"},{"issue":"3","key":"2175_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","volume":"39","author":"CM van Gelder","year":"2016","unstructured":"van Gelder CM, Poelman E, Plug I, Hoogeveen-Westerveld M, van der Beek N, Reuser AJJ, et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis. 2016;39(3):383\u201390.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2175_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","volume":"35","author":"C Regnery","year":"2012","unstructured":"Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, Grunert B, et al. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis. 2012;35(5):837\u201345.","journal-title":"J Inherit Metab Dis"},{"issue":"15","key":"2175_CR29","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med. 2010;362(15):1396\u2013406.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"2175_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ymgme.2019.07.013","volume":"128","author":"E Fern\u00e1ndez-Sim\u00f3n","year":"2019","unstructured":"Fern\u00e1ndez-Sim\u00f3n E, Carrasco-Rozas A, Gallardo E, Gonz\u00e1lez-Quereda L, Alonso-P\u00e9rez J, Belmonte I, et al. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT. Mol Genet Metab. 2019;128(1\u20132):129\u201336.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2175_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.nmd.2014.12.004","volume":"25","author":"LE Case","year":"2015","unstructured":"Case LE, Bjartmar C, Morgan C, Casey R, Charrow J, Clancy JP, et al. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Neuromuscul Disord. 2015;25(4):321\u201332.","journal-title":"Neuromuscul Disord"},{"key":"2175_CR32","doi-asserted-by":"publisher","first-page":"636731","DOI":"10.3389\/fimmu.2021.636731","volume":"12","author":"AS De Groot","year":"2021","unstructured":"De Groot AS, Desai AK, Lelias S, Miah SMS, Terry FE, Khan S, et al. Immune tolerance-adjusted personalized immunogenicity prediction for Pompe disease. Front Immunol. 2021;12:636731.","journal-title":"Front Immunol"},{"key":"2175_CR33","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3389\/fimmu.2020.01727","volume":"11","author":"AK Desai","year":"2020","unstructured":"Desai AK, Baloh CH, Sleasman JW, Rosenberg AS, Kishnani PS. Benefits of prophylactic short-course immune tolerance induction in patients with infantile Pompe disease: demonstration of long-term safety and efficacy in an expanded cohort. Front Immunol. 2020;11:1727.","journal-title":"Front Immunol"},{"issue":"12","key":"2175_CR34","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.nmd.2010.07.277","volume":"20","author":"CI van Capelle","year":"2010","unstructured":"van Capelle CI, van der Beek NA, Hagemans ML, Arts WF, Hop WC, Lee P, et al. Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord. 2010;20(12):775\u201382.","journal-title":"Neuromuscul Disord"},{"key":"2175_CR35","volume-title":"Aids to the examination of the peripheral nervous system, Memorandum No. 45","author":"Medical Research Council","year":"1978","unstructured":"Medical Research Council. Aids to the examination of the peripheral nervous system, Memorandum No. 45. London: Her Majesty\u2019s Stationary Office; 1978."},{"issue":"2","key":"2175_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10545-011-9388-3","volume":"35","author":"CI van Capelle","year":"2012","unstructured":"van Capelle CI, van der Beek NA, de Vries JM, van Doorn PA, Duivenvoorden HJ, Leshner RT, et al. The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients. J Inherit Metab Dis. 2012;35(2):317\u201323.","journal-title":"J Inherit Metab Dis"},{"key":"2175_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1750-1172-7-73","volume":"7","author":"JM de Vries","year":"2012","unstructured":"de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis. 2012;7:73.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2175_CR38","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1164\/rccm.166.4.518","volume":"166","author":"American Thoracic Society\/European Respiratory Society","year":"2002","unstructured":"American Thoracic Society\/European Respiratory Society. ATS\/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002;166(4):518\u2013624.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2175_CR39","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324\u201343.","journal-title":"Eur Respir J"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02175-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02175-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02175-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T19:02:59Z","timestamp":1643828579000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02175-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2175"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02175-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"1 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the medical ethical committee of the Erasmus MC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We received informed consent forms from all participants and\/or their caregivers in this study; all forms are on file and available in case of request. All individual patient data was de-identified.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.M.P. van den Hout, A.T. van der Ploeg, and N.A.M.E. van der Beek, received funding for research, clinical trials and as advisor from various industries working on enzyme-replacement therapy or next-generation therapies in the field of Pompe disease, other lysosomal storage diseases or neuromuscular disorders, under agreements with Erasmus MC University Medical Center and the relevant industry. M. Hoogeveen-Westerveld and E.H. Jacobs performed diagnostic assays for Spark Therapeutics. H.A. van Kooten, I.A.M. Ditters, P.A. van Doorn and W.W.M. Pijnappel declare no potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}